DK0720597T3 - Triarylethylenderivater til terapeutisk anvendelse - Google Patents

Triarylethylenderivater til terapeutisk anvendelse

Info

Publication number
DK0720597T3
DK0720597T3 DK94927182T DK94927182T DK0720597T3 DK 0720597 T3 DK0720597 T3 DK 0720597T3 DK 94927182 T DK94927182 T DK 94927182T DK 94927182 T DK94927182 T DK 94927182T DK 0720597 T3 DK0720597 T3 DK 0720597T3
Authority
DK
Denmark
Prior art keywords
therapeutic use
derivatives
triarylethylene
agents
triarylethylene derivatives
Prior art date
Application number
DK94927182T
Other languages
English (en)
Inventor
Donald P Matthews
Alan J Bitonti
Sickle William A Van
Donald A Kaplan
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/259,797 external-priority patent/US5525633A/en
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of DK0720597T3 publication Critical patent/DK0720597T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94927182T 1993-09-24 1994-08-19 Triarylethylenderivater til terapeutisk anvendelse DK0720597T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12661493A 1993-09-24 1993-09-24
US08/259,797 US5525633A (en) 1993-09-24 1994-06-15 Triaryl-ethylene derivatives
PCT/US1994/009314 WO1995008528A1 (en) 1993-09-24 1994-08-19 Triaryl-ethylene derivatives for use in therapy

Publications (1)

Publication Number Publication Date
DK0720597T3 true DK0720597T3 (da) 1998-10-07

Family

ID=26824862

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94927182T DK0720597T3 (da) 1993-09-24 1994-08-19 Triarylethylenderivater til terapeutisk anvendelse

Country Status (17)

Country Link
US (1) US5684004A (da)
EP (1) EP0720597B1 (da)
JP (1) JPH09503761A (da)
CN (1) CN1131415A (da)
AT (1) ATE165594T1 (da)
AU (1) AU678535B2 (da)
CA (1) CA2171728C (da)
DE (1) DE69409961T2 (da)
DK (1) DK0720597T3 (da)
ES (1) ES2115975T3 (da)
FI (1) FI961339A7 (da)
HU (1) HUT75933A (da)
IL (1) IL111018A0 (da)
NO (1) NO306292B1 (da)
NZ (1) NZ273433A (da)
PL (1) PL177833B1 (da)
WO (1) WO1995008528A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
CN102379684B (zh) 2005-04-28 2014-11-19 普罗透斯数字保健公司 药物信息系统
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(rap)-접합체 투여에 의한 간 질환의 치료
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PL313594A1 (en) 1996-07-08
NO961204D0 (no) 1996-03-25
ES2115975T3 (es) 1998-07-01
US5684004A (en) 1997-11-04
EP0720597B1 (en) 1998-04-29
NZ273433A (en) 1997-11-24
NO961204L (no) 1996-03-25
FI961339A0 (fi) 1996-03-22
CN1131415A (zh) 1996-09-18
DE69409961D1 (de) 1998-06-04
CA2171728A1 (en) 1995-03-30
NO306292B1 (no) 1999-10-18
WO1995008528A1 (en) 1995-03-30
JPH09503761A (ja) 1997-04-15
AU678535B2 (en) 1997-05-29
AU7670794A (en) 1995-04-10
PL177833B1 (pl) 2000-01-31
FI961339L (fi) 1996-03-22
CA2171728C (en) 2001-11-13
IL111018A0 (en) 1994-11-28
EP0720597A1 (en) 1996-07-10
DE69409961T2 (de) 1998-09-10
HUT75933A (en) 1997-05-28
FI961339A7 (fi) 1996-03-22
ATE165594T1 (de) 1998-05-15
HU9600727D0 (en) 1996-05-28

Similar Documents

Publication Publication Date Title
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ID23374A (id) Halogenopirimidin
NO990405L (no) Substituerte N-(indol-2-karbonyl)-glycinamider og derivater som antidiabetiske midler
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
TR200200068T2 (tr) Nematisital triflüorobütenler
PT1017659E (pt) Tetra-hidronaftalenos substituidos e compostos analogos
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
ATE167670T1 (de) N-alkylthiopolyaminderivate als radioprotektive mittel
BR9711586A (pt) Compostos e uso dos mesmo
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
ATE203519T1 (de) Chinolinderivate als antimalariamittel
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
FI970448A7 (fi) N-substituoituja 3-atsobisyklo(3.2.0)heptaanijohdannaisia,jotka ovat k äyttökelpoisia neuroleptisina aineina
MY105128A (en) Bu-3608 derivatives.
BG100248A (bg) Инхибитори на скваленсинтетаза
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
ES2152315T3 (es) Xamoneline tartrato.
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
ID27733A (id) Metoksiminofenilasetamida
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
FR2710245B3 (fr) Composition amaigrissante.
BR9611904A (pt) Dioxidos de ditiazol
FI945414A0 (fi) Menetelmä N,N-disubstituoidun aminofenolin valmistamiseksi
UA16247A1 (uk) N-(3-ХЛОРО-1,4-HАФТОХІHОHІЛ-2)-2-Д, alРha-АСПАРАГІHОВУ КИСЛОТА, ЩО ПРОЯВЛЯЄ КАРДІОСТИМУЛЮЮЧІ ВЛАСТИВОСТІ